Skip to Content
Merck’s Gardasil is a potent vaccine against HPV, a sexually transmitted disease that can cause cervical cancer. But until recently, cost and production constraints limited its reach. Merck has now committed more than $1 billion to expand capacity, with a focus on underserved countries. Merck more than doubled global supply of Gardasil between 2017 and 2020 and is on track to do so again by 2023.
Courtesy of Merck
Lists ranking Merck
RANK42
Change the World - 2022Fortune's annual list dedicated to the idea that b...READ MOREview in list
RANK10
10 Best Large Workplaces in Biotechnology and Pharmaceuticals - 2022See which workplaces made this year's list....READ MOREview in list
RANK262
Global 500 - 2022Aggregate sales hit $37.8 trillion last year—an in...READ MOREview in list
RANK32
35 Best Large Workplaces in New York - 2022The companies on this year's list stand out for ce...READ MOREview in list
RANK71
Fortune 500 - 2022This year’s Fortune 500 marks the 68th running of ...READ MOREview in list
RANK41
World’s Most Admired Companies - 2022Just as it dominates our economy, Big Tech now dom...READ MOREview in list
RANK100
100 Best Companies to Work For - 2021Our 2021 list of the 100 best companies to work fo...READ MOREview in list